

RESEARCH

Open Access



Evaluation of the safety and efficacy of extracorporeal carbon dioxide removal in the critically ill using the PrismaLung+ device

Ravindranath Tiruvoipati^{1,2,3*} , Jarryd Ludski¹, Sachin Gupta^{1,2}, Ashwin Subramaniam^{1,2,3,4} ,
Mallikarjuna Ponnappa Reddy^{1,2,5} , Eldho Paul^{3,6} and Kavi Haji^{1,2,7}

Abstract

Background Several extracorporeal carbon dioxide removal (ECCO₂R) devices are currently in use with variable efficacy and safety profiles. PrismaLung+ is an ECCO₂R device that was recently introduced into clinical practice. It is a minimally invasive, low flow device that provides partial respiratory support with or without renal replacement therapy. Our aim was to describe the clinical characteristics, efficacy, and safety of PrismaLung+ in patients with acute hypercapnic respiratory failure.

Methods All adult patients who required ECCO₂R with PrismaLung+ for hypercapnic respiratory failure in our intensive care unit (ICU) during a 6-month period between March and September 2022 were included.

Results Ten patients were included. The median age was 55.5 (IQR 41–68) years, with 8 (80%) male patients. Six patients had acute respiratory distress syndrome (ARDS), and two patients each had exacerbations of asthma and chronic obstructive pulmonary disease (COPD). All patients were receiving invasive mechanical ventilation at the time of initiation of ECCO₂R. The median duration of ECCO₂R was 71 h (IQR 57–219). A significant improvement in pH and PaCO₂ was noted within 30 min of initiation of ECCO₂R. Nine patients (90%) survived to weaning of ECCO₂R, eight (80%) survived to ICU discharge and seven (70%) survived to hospital discharge. The median duration of ICU and hospital stays were 14.5 (IQR 8–30) and 17 (IQR 11–38) days, respectively. There were no patient-related complications with the use of ECCO₂R. A total of 18 circuits were used in ten patients (median 2 per patient; IQR 1–2). Circuit thrombosis was noted in five circuits (28%) prior to reaching the expected circuit life with no adverse clinical consequences.

Conclusion(s) PrismaLung+ rapidly improved PaCO₂ and pH with a good clinical safety profile. Circuit thrombosis was the only complication. This data provides insight into the safety and efficacy of PrismaLung+ that could be useful for centres aspiring to introduce ECCO₂R into their clinical practice.

Keywords Hypercapnia, Respiratory failure, Respiratory acidosis, Extracorporeal therapies, PrismaLung+

*Correspondence:

Ravindranath Tiruvoipati
travindranath@hotmail.com

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background and rationale

Acute respiratory failure is one of the most common indications for admission of patients to the intensive care unit (ICU). Many of these patients require the assistance of invasive mechanical ventilation (IMV) in the management of respiratory failure. A strategy of preventing ventilator induced lung injury (VILI) by reducing inspiratory pressures and the driving pressure on IMV has been shown to reduce mortality [1, 2]. The current standard of care in treating patients with acute hypoxic respiratory failure is to use low tidal volume (<6 ml/kg predicted body weight) ventilation [3]. One of the effects of such a ventilation strategy is the development of hypercapnia and related respiratory acidosis. Several recent studies have highlighted the adverse effects of hypercapnia when associated with lung protective ventilation [4–8]. Based on the evidence from these studies, hypercapnia should be avoided or actively treated when associated with lung protective ventilation.

There are several minimally invasive extracorporeal carbon dioxide removal (ECCO₂R) devices that are currently available for the management of patients with severe hypercapnic respiratory failure [9–13]. Most of these devices provide partial respiratory support as compared to extracorporeal membrane oxygenation (ECMO), where total respiratory support can be provided. These devices are mainly used to remove CO₂ from the blood to provide lung protective ventilation [14, 15]. Most of these less invasive devices are efficient in clearing CO₂ but do not provide significant oxygenation [12, 13, 16]. The cannulas used to access blood vessels are smaller (13–16 F) in low-flow ECCO₂R devices but can be cannulas similar to ECMO in high-flow devices. The anticoagulation targets are similar to other extracorporeal devices, such as renal replacement therapy circuits and ECMO devices. A recent study, however, observed a higher incidence of bleeding and haemolysis with low-flow ECCO₂R devices [17].

The use of minimally invasive ECCO₂R devices was reported in several studies with satisfactory clearance of carbon dioxide [9–12, 18]. However, some studies reported a higher incidence of complications such as haemolysis, bleeding, and inadequacy of obtaining satisfactory carbon dioxide clearance with the use of low-flow devices ECCO₂R devices [17, 19–21].

One of the newer devices is called PrismaLung+ [22], which was recently introduced to clinical practice. PrismaLung+ is a low flow venovenous ECCO₂R device that can provide CO₂ removal with or without simultaneously providing renal replacement therapy.

Aims and objectives

This study aimed to evaluate the safety and efficacy of ECCO₂R with PrismaLung+ in mechanically ventilated critically ill patients.

Methods

Ethics approval

The human research ethics committees of Peninsula Health reviewed the study proposal and waived the requirement for a full ethics committee application (QA/89504/PH-2022-330245). This was because the study was seen as a retrospective audit of data routinely collected for patient care and not experimental research. Consent from individual patients was not required, since the research was limited to the use of information previously collected during normal care and the patients were not identifiable.

All mechanically ventilated patients with acute or acute-on-chronic hypercapnic respiratory failure, managed with ECCO₂R over a period of 6 months (March 2022 to September 2022) in our hospital were included.

ECCO₂R with PrismaLung+

PrismaLung+ (Fig. 1) is a novel low flow venovenous device that integrates renal and respiratory extracorporeal supports. A detailed description of this device is provided elsewhere [23, 24]. It incorporates a gas exchange membrane made of polymethylpentene hollow-fiber mats, into Prisma (Baxter Healthcare Pty Ltd.) renal replacement system with or without the use of a haemofilter within the circuit [24]. PrismaLung+ has a larger gas exchange membrane surface area (0.8 m²) as compared to the earlier version of PrismaLung+ with a lower surface area (0.35 m²) making this a more effective device [24]. The total priming volume of the circuit is 273 mL.

Patient management on ECCO₂R

Access to blood flow was obtained by a 13F double-lumen catheter either via a femoral or jugular vein. Catheter insertion was performed using real-time ultrasound guidance. Heparin was used for anticoagulation, aiming for an Activated Partial Thromboplastin Time (APTT) of 50–70 s. Blood flow was established at a rate of 200 mL/min to 250 mL/min. Oxygen was used as sweep gas. The sweep gas flow was gradually increased to 10 L/min to provide effective ECCO₂R. After lung recovery, ECCO₂R weaning was initiated by down-titrating sweep gas flow and thereby reducing the amount of CO₂ removal to zero. After confirming adequate respiratory function, ECCO₂R was disconnected from the patient at the discretion of the treating intensivist.




Fig. 1 PrismaLung+

Low tidal volume (≤ 6 mL/kg ideal body weight), and low-pressure ventilation were targeted for all patients included in this study, with no pre-specified protocol on the mode of IMV. Asthmatic patients were mechanically ventilated with a low tidal volume (5–6 mL/kg), a low respiratory rate (10–12 breaths/min), and a short inspiratory time associated with prolonged expiratory time to avoid dynamic hyperinflation.

Indications for the use of ECCO₂R

Patients were managed with ECCO₂R at the discretion of the treating intensivist if the patient was receiving IMV but could not be ventilated with lung protective ventilation (tidal volumes ≤ 6 mL/kg of ideal body weight) due to hypercapnic respiratory failure (respiratory acidosis (pH < 7.25 and pCO₂ > 55 mmHg).

Contraindications to ECCO₂R

- Contraindication for limited anticoagulation (Heparinisation to achieve an APTT of 50–70 s or an activated clotting time (ACT) of 150–180 s).
- Platelet count of less than 75,000/mm³.
- Patients who had established treatment limitations (i.e., not for cardiopulmonary resuscitation, or admitted to ICU for palliative care or organ donation purposes, not for intubation, mechanical ventilation, and not for continuous renal replacement therapy in ICU).

Primary outcome measure

CO₂ clearance and improvement in pH with the use of ECCO₂R.

Secondary outcome measures

- Complications associated with ECCO₂R
- Survival to weaning from ECCO₂R, ICU and hospital discharge.

Complications: Classified as patient-related or device-related.

Patient-related:

- Bleeding: Clinically significant bleeding that required blood transfusions, the need to stop anticoagulation, the need for surgery or any other interventions to stop bleeding during the ECCO₂R
- Bleeding from the catheter site
- Intracranial bleeding
- Disseminated intravascular coagulation or thromboembolism
- Pneumothorax
- Cardiac arrhythmias
- Hypothermia
- Haemodynamic instability: Tachycardia or hypotension (<90 mmHg of systolic blood pressure) at the commencement of ECCO₂R that may be attributed to ECCO₂R initiation.
- Catheter infection: Infection at catheter site that resulted in bacteraemia.
- Clinically significant haemolysis: Jaundice or anaemia that is not due to another recognisable cause.
- Severe thrombocytopenia (<50,000/mm³).

Device-related:

- Circuit thrombosis: Clotting of membrane lung or the circuit that needed circuit replacement prior to reaching the expected circuit life (within 72 h of starting the circuit).
- Pump malfunction, inability to start ECCO₂R or air in circuit.

Statistical analysis

Categorical variables are presented as counts and percentages and continuous variables as medians and inter-quartile ranges (IQR). Changes in pH, PaCO₂, PaO₂, peak inspiratory pressure and minute ventilation from baseline values prior to initiation of PrismaLung+ and at successive time points were assessed and summarised using means and standard errors. To account for repeat measures, data were analysed using the PROC MIXED procedure in SAS with each patient treated as a random effect. Time was treated as a categorical variable to facilitate specific comparisons. A two-sided $P < 0.05$ indicated

statistical significance. All analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC, USA) and SPSS version 22 (IBM SPSS, Armonk, NY).

Results

A total of ten patients received ECCO₂R during the study period. The demographic, diagnosis, and outcome data are presented in Table 1. A summary of the patients, including duration of ECCO₂R, complications, survival and the cause of death is presented in Table 2. Figure 2 shows changes in pH and PaCO₂ before initiation and at successive time points. Figure 3 shows changes in minute ventilation and peak inspiratory pressure before initiation and at successive time points. Table 3 shows mean changes in minute ventilation, peak inspiratory pressure, PaCO₂, PaO₂, pH, respiratory rate and tidal volume before initiation and at successive time points. A significant reduction in PaCO₂ and improvement in pH were noted within 30 min of initiation of ECCO₂R. These clinically important changes persisted throughout the

Table 1 Summary of clinical characteristics and outcomes of patients receiving ECCO₂R

Variable ($n = 10$ patients)	
Age in years (median; IQR)	55.5 (41–68)
Male, n (%)	8 (80%)
ARDS, n (%)	6 (60%)
COPD, n (%)	2 (20%)
Asthma, n (%)	2 (20%)
Serum Bilirubin (umol/L) (median; IQR)	11 (6–16)
Serum Albumin (g/L) (median; IQR)	30 (26–35)
Urea (mmol/L) (median; IQR)	15 (11–21)
Creatinine (umol/L) (median; IQR)	75 (64–118)
Hb (median; IQR)	11 (10–12)
Platelets (median; IQR)	234 (159–331)
WCC (median; IQR)	15 (11–21)
APACHE III score (median; IQR)	47(41–56)
Vascular access—femoral vein, n (%)	9 (90%)
Vascular access—femoral vein, n (%)	1 (10%)
Days on IMV prior to ECCO ₂ R (median; IQR)	0.5 (0–1)
Days of IMV post ECCO ₂ R (median; IQR)	4 (1–12)
Total duration of Mechanical ventilation (days) (median; IQR)	13.5 (6–26)
Total Duration of ECCO ₂ R (hours) (median; IQR)	71 (57–219)
Total Duration of ICU stay (days) (median; IQR)	14.5 (8–30)
Number of ECCO ₂ R kits used per patient (median; IQR)	1.5 (1–2)
Prone Position ventilation, n (%)	1 (10%)
Inhaled Nitric oxide, n (%)	1 (10%)
Survival to ECCO ₂ R weaning, n (%)	9 (90)
Survival to ICU discharge, n (%)	8 (80)
Survival to hospital discharge, n (%)	7 (70)

Table 2 Summary of patients managed with PrismaLung+

Patient	Age	Sex	Diagnosis	Duration of ECCO ₂ R (h)	Complications during ECCO ₂ R	Survival to removal of ECCO ₂ R	Survival to ICU discharge	Survival to hospital discharge	Cause of death
1	68	Male	ARDS	261	Circuit thrombosis < 72 h	Survived	Died	Died	Sepsis secondary to VAP
2	41	Male	ARDS	71	Circuit thrombosis < 72 h	Survived	Survived	Survived	–
3	37	Female	ASTHMA	69	Circuit thrombosis < 72 h	Survived	Survived	Survived	–
4	72	Male	ARDS	57	–	Survived	Survived	Died	Aspiration pneumonitis
5	43	Male	ARDS	31.5	Circuit thrombosis < 72 h	Survived	Survived	Survived	–
6	33	Male	ARDS	29	–	Survived	Survived	Survived	–
7	54	Female	COPD	219	–	Survived	Survived	Survived	–
8	57	Male	ASTHMA	71	–	Survived	Survived	Survived	–
9	78	Male	ARDS	275	–	Died	Died	Died	COVID-19 pneumonia
10	58	Male	COPD	89	–	Survived	Survived	Survived	–

therapy. The minute ventilation showed a reduction by day 1 of ECCO₂R initiation. A reduction in peak inspiratory pressures was noted on day 2 after the initiation of ECCO₂R.

There were no bleeding complications noted with the use of ECCO₂R, but two patients required blood transfusions (one patient received four units and the other two units) largely due to loss of blood due to circuit changes and haemodilution. There were no other patient-related complications. A total of 18 circuits were used in ten patients (median 2 per patient; IQR 1–2). Circuit thrombosis was noted in five circuits (28%) that required replacement of the circuit prior to reaching the expected circuit life. It was due to a lack of anticoagulation at the time of initiation of ECCO₂R, in one of these patients. No other device-related complications were noted. The survival to weaning of ECCO₂R, ICU, hospital discharge, and cause of death are presented in Tables 1 and 2. Three patients required tracheostomy during their ICU course. All patients who survived were discharged home.

Discussion

Key findings

In this 10-patient case series to assess the efficacy of PrismaLung+ in correcting hypercapnic acidosis, we found that ECCO₂R significantly improved hypercapnic acidosis within 30 min and maintained normal pH and normocapnia throughout the therapy while reducing minute ventilation and inspiratory pressure. There were no patient-related complications associated with the use of this device. Circuit thrombosis within 72 h of initiating ECCO₂R was noted in four patients and was the only device-related complication that was noted in this

study. The factors that may have contributed included poor vascular access that was noted in one patient due to the catheter inserted in the jugular vein and inadequate anticoagulation in another patient. Experience with the use of the device may help reduce the incidence of such complications.

Relationship with previous studies

Several ECCO₂R devices are currently in use with variable performances. PrismaLung+ is a novel device with the advantage of providing both ECCO₂R and renal replacement therapy (RRT) with a single access catheter. The similarity of the device with RRT makes use of this device easier in intensive care units that currently use RRT. The results of our study in terms of CO₂ removal are comparable to other studies with higher blood flows (350–550 mL/min) [16, 21]. This is due to the fact that the larger surface area of the membrane offsets the relative lower blood flow rates of 200–250 mL/min that were able to achieve with PrismaLung+ [25].

Our indication for the use of PrismaLung+ was different from some of the recent studies, where ECCO₂R devices were used to target ultra-protective ventilation [9, 21]. Targeting ultra-protective ventilation did not improve 90-day mortality and was associated with lower ventilation-free days in patients with a PaO₂/FiO₂ of less than 150 mmHg [21]. Given these results, our aim was to first investigate if PrismaLung+ had the efficacy of removing CO₂ with comparably lower flow rates (200 to 250 mL/min) when the low tidal volume (≤ 6 mL/kg of ideal body weight) caused hypercapnic acidosis. Our results suggest that PrismaLung+ was effective in the removal of CO₂ and thereby correcting the hypercapnic




Fig. 2 Changes in pH, PCO₂ and PO₂ before initiation and at successive time points. Error bars represent 95% confidence intervals




Fig. 3 Changes in peak inspiratory pressure, minute ventilation, tidal volume and respiratory rate before initiation and at successive time points. Error bars represent 95% confidence intervals

acidosis associated with low tidal volume ventilation. The safety and efficacy of PrismaLung+ with ultralow tidal volume ventilation remain to be evaluated.

From the published data, ECCO₂R devices while being effective in removing CO₂, they have not been shown to improve survival, especially in patients with severe ARDS [9, 21]. Such patients with severe ARDS, are likely to benefit from VV ECMO [26]. Patients with mild to moderate ARDS associated with hypercapnic acidosis may benefit from low-flow ECCO₂R devices [16].

The published literature on the use of this device is limited [20, 27, 28], with only one study reporting on the exclusive use of PrismaLung+ in mechanically ventilated patients with hypercapnic acidosis [27]. Similar to the results of our study, the study by Consales and colleagues reported a rapid correction of hypercapnic acidosis with no treatment-related complications [27]. The study by Giraud and colleagues [20] reported that PrismaLung+ was not able to remove sufficient CO₂, to correct hypercapnic acidosis in three patients with severe COPD. In our case series, two patients had COPD, and PrismaLung+ satisfactorily improved hypercapnic acidosis.

In previous studies, low-flow ECCO₂R devices were shown to have a higher proportion of haemolysis, bleeding, and membrane clotting as compared to high-flow

ECCO₂R devices [17, 19]. In our study, we did not find any similar clinical complications with PrismaLung+ such as bleeding or haemolysis other than the clotting of the circuit within 72 h after initiation of the ECCO₂R in five circuits.

Study implications and future directions

This study provides preliminary data on the safety and efficacy of ECCO₂R with PrismaLung+ in mechanically ventilated patients. Further data on the efficacy of this device is required to determine whether it will reduce tidal volumes and driving pressure and thus improve survival in patients with ARDS.

Strengths and limitations

Strengths: This study provides further evidence of the use of PrismaLung+ as an intervention to correct hypercapnic acidosis in patients receiving low tidal volume ventilation. The study results provide insights into the clinical efficacy and safety profile of the device that may help clinicians who may be considering the introduction of ECCO₂R to their clinical practice. It reports data on physiological and patient-centred outcomes, especially the safety of this device.

Table 3 Mean changes in minute ventilation, peak inspiratory pressure, PaCO₂, PaO₂, pH, respiratory rate and tidal volume before initiation and at successive time points

Variable	Estimated change from before initiation	Standard error	P value
Minute ventilation			
At Initiation	0.870	0.503	0.090
1–2 h	0.790	0.503	0.123
6–8 h	0.720	0.503	0.159
Day 1	1.508	0.540	0.008
Day 2	0.464	0.595	0.439
Day 3	0.486	0.778	0.535
At Removal	1.447	0.519	0.008
24 h post removal	−0.629	0.564	0.271
Peak inspiratory pressure (PIP)			
At Initiation	1.000	2.947	0.736
1–2 h	0.000	2.947	1.000
6–8 h	2.200	2.947	0.459
Day 1	5.599	3.160	0.083
Day 2	9.879	3.483	0.007
Day 3	6.007	4.541	0.193
At Removal	5.593	3.042	0.073
24 h post removal	9.288	3.479	0.011
PaCO ₂			
At Initiation	23.430	6.110	0.0004
1–2 h	29.580	6.110	<0.0001
6–8 h	30.580	6.110	<0.0001
Day 1	38.759	6.243	<0.0001
Day 2	36.636	6.455	<0.0001
Day 3	37.263	7.233	<0.0001
At Removal	37.580	6.110	<0.0001
24 h post removal	38.263	6.239	<0.0001
PaO ₂			
At Initiation	3.033	10.188	0.767
1–2 h	14.756	10.188	0.155
6–8 h	17.956	10.188	0.085
Day 1	20.634	10.568	0.057
Day 2	1.628	10.838	0.881
Day 3	13.479	12.551	0.289
At Removal	18.211	10.188	0.081
24 h post removal	9.008	10.557	0.398
pH			
At Initiation	−0.107	0.037	0.006
1–2 h	−0.148	0.037	0.0002
6–8 h	−0.166	0.037	<0.0001
Day 1	−0.237	0.039	<0.0001
Day 2	−0.211	0.041	<0.0001
Day 3	−0.204	0.048	0.0001
At Removal	−0.244	0.037	<0.0001
24 h post removal	−0.271	0.039	<0.0001

Table 3 (continued)

Variable	Estimated change from before initiation	Standard error	P value
Respiratory rate			
At Initiation	0.999	1.056	0.348
1–2 h	0.599	1.056	0.573
6–8 h	0.399	1.056	0.707
Day 1	3.314	1.152	0.006
Day 2	−0.172	1.293	0.894
Day 3	0.578	1.746	0.742
At Removal	−0.30	1.056	0.778
24 h post removal	−0.873	1.150	0.452
Tidal volume			
1–2 h	−18.40	32.237	0.572
6–8 h	−12.90	32.237	0.691
Day 1	−69.591	35.078	0.055
Day 2	−42.275	39.304	0.289
Day 3	−62.782	52.829	0.242
At Removal	−8.767	33.507	0.795
24 h post removal	−47.836	36.90	0.203

Limitations

Our study included patients, in whom lower tidal volumes were used. The efficacy of this device to provide satisfactory CO₂ clearance in patients receiving ultralow tidal volumes was not evaluated in our study. We used an increase in serum bilirubin or anaemia that is not due to other obvious causes, as a marker of haemolysis. They may not be as sensitive as other investigations, such as haptoglobin or free haemoglobin for haemolysis. Given the single-centre experience of our study, the results may not be generalisable.

Conclusions

ECCO₂R with the use of PrismaLung+ appears safe, and effective in correcting hypercapnic acidosis. This data provides insight into PrismaLung+ performance and potential complications that could be useful for centres aspiring to introduce ECCO₂R into their clinical practice. Further studies are required to evaluate its use in reducing driving pressure and associated lung injury, which may contribute to an improvement in clinical outcomes, including a reduction in the duration of mechanical ventilation and the associated morbidity and mortality.

Abbreviations

ACT	Activated clotting time
APTT	Activated Partial Thromboplastin Time
ARDS	Acute respiratory distress syndrome
COPD	Chronic obstructive pulmonary disease

ECCO ₂ R	Extracorporeal carbon dioxide removal
ECMO	Extracorporeal membrane oxygenation
ICU	Intensive care unit
IMV	Invasive mechanical ventilation
IQR	Interquartile range
PaCO ₂	Partial pressure of carbon dioxide in arterial blood
PaO ₂	Partial pressure of oxygen in arterial blood
RRT	Renal replacement therapy
VILI	Ventilator induced lung injury

Acknowledgements

Not applicable.

Author contributions

RT: conceptualization, methodology, original draft writing, project administration, review and editing. JL and SG: data curation, review and editing. AS, MR and KH: draft review and revision and editing. EP: formal analysis, draft review and revision and editing. All authors read and approved the final manuscript.

Funding

No funding was available for this study.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Declarations

Ethics approval and consent to participate

Ethics approval was obtained from the Human Research and Ethics Committee of Peninsula Health (Reference number QA/89504/PH-2022-330245). Informed consent was waived by ethics committees as data were already collected as part of routine quality assurance processes.

Consent for publication

Not applicable.

Competing interests

RT was an invited speaker at a Baxter sponsored meeting in March 2023. Rest of the authors declare that they have no competing interests.

Author details

¹Department of Intensive Care Medicine, Frankston Hospital, Peninsula Health, Frankston, VIC 3199, Australia. ²Division of Medicine, Peninsula Clinical School, Monash University, Frankston, VIC, Australia. ³ANZIC-RC, School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Road, Melbourne, VIC 3004, Australia. ⁴Department of Intensive Care Medicine, Dandenong Hospital, Dandenong, Australia. ⁵Department of Intensive Care, Calvary Hospital, Canberra, ACT, Australia. ⁶Alfred Hospital, Melbourne, VIC, Australia. ⁷Department of Surgery, University of Melbourne, Melbourne, VIC, Australia.

Received: 2 June 2023 Accepted: 5 August 2023

Published online: 18 August 2023

References

- Hickling KG, Walsh J, Henderson S, Jackson R. Low mortality rate in adult respiratory distress syndrome using low-volume, pressure-limited ventilation with permissive hypercapnia: a prospective study. *Crit Care Med*. 1994;22:1568–78.
- Amato MBP, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome. *N Engl J Med*. 2015;372:747–55.
- Acute Respiratory Distress Syndrome Network; Roy G, Brower MAM, Alan Morris, David Schoenfeld, B Taylor Thompson, Arthur Wheeler. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. *N Engl J Med* 2000;342:1301–8.
- Barnes T, Zochios V, Parhar K. Re-examining Permissive Hypercapnia in ARDS: A Narrative Review. *Chest*. 2018;154:185–95.
- Nin N, Muriel A, Peñuelas O, et al. Severe hypercapnia and outcome of mechanically ventilated patients with moderate or severe acute respiratory distress syndrome. *Intensive Care Med*. 2017;43:200–8.
- Tiruvoipati R, Pilcher D, Buscher H, Botha J, Bailey M. Effects of hypercapnia and hypercapnic acidosis on hospital mortality in mechanically ventilated patients. *Crit Care Med*. 2017;45:e649–56.
- Gendreau S, Geri G, Pham T, Veillard-Baron A, Mekontso-Dessap A. The role of acute hypercapnia on mortality and short-term physiology in patients mechanically ventilated for ARDS: a systematic review and meta-analysis. *Intensive Care Med*. 2022;9:1–18.
- Tiruvoipati R, Pilcher D, Botha J, Buscher H, Simister R, Bailey M. Association of hypercapnia and hypercapnic acidosis with clinical outcomes in mechanically ventilated patients with cerebral injury. *JAMA Neurol*. 2018;75:818–26.
- Bein T, Weber-Carstens S, Goldmann A, et al. Lower tidal volume strategy (approximately 3 ml/kg) combined with extracorporeal CO₂ removal versus “conventional” protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study. *Intensive Care Med*. 2013;39:847–56.
- Braune S, Sieweke A, Brettner F, et al. The feasibility and safety of extracorporeal carbon dioxide removal to avoid intubation in patients with COPD unresponsive to noninvasive ventilation for acute hypercapnic respiratory failure (ECLAIR study): multicentre case-control study. *Intensive Care Med*. 2016;42:1437–44.
- Brunston RL Jr, Zwischenberger JB, Tao W, Cardenas VJ Jr, Traber DL, Bidani A. Total arteriovenous CO₂ removal: simplifying extracorporeal support for respiratory failure. *Ann Thorac Surg*. 1997;64:1599–604.
- Combes A, Fanelli V, Pham T, Ranieri VM. Feasibility and safety of extracorporeal CO₂ removal to enhance protective ventilation in acute respiratory distress syndrome: the SUPERNOVA study. *Intensive Care Med*. 2019;45:592–600.
- Tiruvoipati R, Buscher H, Winearls J, et al. Early experience of a new extracorporeal carbon dioxide removal device for acute hypercapnic respiratory failure. *Crit Care Resus*. 2016;18:261–9.
- Terragni PP, Del Sorbo L, Mascia L, et al. Tidal volume lower than 6 ml/kg enhances lung protection: role of extracorporeal carbon dioxide removal. *Anesthesiology*. 2009;111:826–35.
- Staudinger T. Update on extracorporeal carbon dioxide removal: a comprehensive review on principles, indications, efficiency, and complications. *Perfusion*. 2020;35:492–508.
- Tiruvoipati R, Akkanti B, Dinh K, et al. Extracorporeal Carbon Dioxide Removal With the Hemolung in Patients With Acute Respiratory Failure: A Multicenter Retrospective Cohort Study. *Crit Care Med*. 2023;51:892.
- Combes A, Tonetti T, Fanelli V, et al. Efficacy and safety of lower versus higher CO(2) extraction devices to allow ultraproductive ventilation: secondary analysis of the SUPERNOVA study. *Thorax*. 2019;74:1179–81.
- Conrad SA, Zwischenberger JB, Grier LR, Alpard SK, Bidani A. Total extracorporeal arteriovenous carbon dioxide removal in acute respiratory failure: a phase I clinical study. *Intensive Care Med*. 2001;27:1340–51.
- Augy JL, Aissaoui N, Richard C, et al. A 2-year multicenter, observational, prospective, cohort study on extracorporeal CO(2) removal in a large metropolitan area. *J Intensive Care*. 2019;7:45.
- Giraud R, Banfi C, Assouline B, De Charrière A, Bendjelid K. Very low blood flow carbon dioxide removal system is not effective in a chronic obstructive pulmonary disease exacerbation setting. *Artif Organs*. 2021;45:479–87.
- McNamee JJ, Gillies MA, Barrett NA, et al. Effect of Lower Tidal Volume Ventilation Facilitated by Extracorporeal Carbon Dioxide Removal vs Standard Care Ventilation on 90-Day Mortality in Patients With Acute Hypoxemic Respiratory Failure: The REST Randomized Clinical Trial. *JAMA* 2021.
- Hospach I, Goldstein J, Harenski K, et al. In vitro characterization of PrismaLung+: a novel ECCO(2)R device. *Intensive Care Med Exp*. 2020;8:14.
- Godet T, Combes A, Zogheib E, et al. Novel CO₂ removal device driven by a renal-replacement system without hemofilter A first step experimental validation. *Anaesthesia*. 2015;34:135–40.
- Hospach I, Goldstein J, Harenski K, et al. In vitro characterization of PrismaLung+: a novel ECCO2R device. *Intensive Care Med Exp*. 2020;8:14.
- Karagiannis C, Strassmann S, Brodie D, et al. Impact of membrane lung surface area and blood flow on extracorporeal CO(2) removal during severe respiratory acidosis. *Intensive Care Med Exp*. 2017;5:34.

26. Combes A, Peek GJ, Hajage D, et al. ECMO for severe ARDS: systematic review and individual patient data meta-analysis. *Intensive Care Med.* 2020;46:2048–57.
27. Consales G, Zamidei L, Turani F, et al. Combined Renal-Pulmonary Extracorporeal Support with Low Blood Flow Techniques: A Retrospective Observational Study (CICERO Study). *Blood Purif.* 2022;51:299–308.
28. Winiszewski H, Aptel F, Belon F, et al. Daily use of extracorporeal CO(2) removal in a critical care unit: indications and results. *J Intensive Care.* 2018;6:36.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

